S. Christopher Linthwaite and Gajus Worthington

Oct 19, 2016

Fluidigm has appointed S. Christopher Linthwaite as CEO and member of the board of directors. He succeeds Gajus Worthington, who has stepped down from his positions as CEO and board member. Linthwaite joined Fluidigm as president and chief operating officer earlier this year. He has also served as a senior business executive with Invitrogen, Life Technologies, and Thermo Fisher Scientific.

Breaking News

FDA Grants Marketing Authorization for Cue Health COVID-19 At-Home, Molecular Test
Germline Genetic Testing Rates in Cancer Patients Low in California, Georgia, Study Finds
BabySeq Project Unearths Actionable Genetic Variants Impacting Infants, Parents
Illumina Appeals FTC's Order to Divest Grail, Cites Government Overreach
AccuStem, University Hospitals Partner to Establish Clinical Utility of Cancer Recurrence Test

The Scan

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.

Active Lifestyle Linked to Type 2 Diabetes Prevention in People at High Genetic Risk

A study in the British Journal of Sports Medicine shows that an active lifestyle goes a long way in type 2 diabetes prevention.

Beneficial, Harmful Effects of Introgression Between Wild and Domesticated European Grapes

A paper in PNAS shows that European wild grapevines were an important resource for improving the flavor of cultivated wine grapes.

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.